Download PDF
Int J Angiol 2018; 27(01): 001-012
DOI: 10.1055/s-0037-1613678
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

AGE–RAGE Stress, Stressors, and Antistressors in Health and Disease

Kailash Prasad
1   Department of Physiology, University of Saskatchewan, College of Medicine, Saskatoon, Canada
,
Manish Mishra
1   Department of Physiology, University of Saskatchewan, College of Medicine, Saskatoon, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
28 December 2017 (online)

    Permissions and Reprints

Abstract

Adverse effects of advanced glycation end-products (AGEs) on the tissues are through nonreceptor- and receptor-mediated mechanisms. In the receptor-mediated mechanism, interaction of AGEs with its cell-bound receptor of AGE (RAGE) increases generation of oxygen radicals, activates nuclear factor-kappa B, and increases expression and release of pro-inflammatory cytokines resulting in the cellular damage. The deleterious effects of AGE and AGE–RAGE interaction are coined as “AGE-RAGE stress.” The body is equipped with defense mechanisms to counteract the adverse effects of AGE and RAGE through endogenous enzymatic (glyoxalase 1, glyoxalase 2) and AGE receptor-mediated (AGER1, AGER2) degradation of AGE, and through elevation of soluble receptor of AGE (sRAGE). Exogenous defense mechanisms include reduction in consumption of AGE, prevention of AGE formation, and downregulation of RAGE expression. We have coined AGE and RAGE as “stressors” and the defense mechanisms as “anti-stressors.” AGE–RAGE stress is defined as a shift in the balance between stressors and antistressors in the favor of stressors. Measurements of stressors or antistressors alone would not assess AGE–RAGE stress. For true assessment of AGE–RAGE stress, the equation should include all the stressors and antistressors. The equation for AGE–RAGE stress, therefore, would be the ratio of AGE + RAGE/sRAGE + glyoxalase1 + glyoxalase 2 + AGER1 +AGER2. This is, however, not practical in patients. AGE–RAGE stress may be assessed simply by the ratio of AGE/sRAGE. A high ratio of AGE/sRAGE indicates a relative shift in stressors from antistressors, suggesting the presence of AGE–RAGE stress, resulting in tissue damage, initiation, and progression of the diseases and their complications.

Keywords

advanced glycation end-products (AGE) - receptor for AGE (RAGE) - soluble receptor for AGE (sRAGE) - AGE–RAGE stress - stressors - antistressors - glyoxalase 1 - glyoxalase 2 - AGER1 - AGER2
 

  • References

  • 1 Del Turco S, Basta G. An update on advanced glycation endproducts and atherosclerosis. Biofactors 2012; 38 (04) 266-274
    CrossrefPubMedGoogle Scholar
  • 2 Falcone C, Emanuele E, D'Angelo A. , et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005; 25 (05) 1032-1037
    CrossrefPubMedGoogle Scholar
  • 3 McNair ED, Wells CR, Qureshi AM. , et al. Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients. Int J Angiol 2009; 18 (04) 187-192
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Prasad K, Mishra M. Do advanced glycation end products and its receptor play a role in pathophysiology of hypertension?. Int J Angiol 2017; 26 (01) 1-11
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 McNulty M, Mahmud A, Feely J. Advanced glycation end-products and arterial stiffness in hypertension. Am J Hypertens 2007; 20 (03) 242-247
    CrossrefPubMedGoogle Scholar
  • 6 Hudson BI, Moon YP, Kalea AZ. , et al. Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS). Atherosclerosis 2011; 216 (01) 192-198
    CrossrefPubMedGoogle Scholar
  • 7 Caspar-Bell G, Dhar I, Prasad K. Advanced glycation end products (AGEs) and its receptors in the pathogenesis of hyperthyroidism. Mol Cell Biochem 2016; 414 (1-2): 171-178
    CrossrefPubMedGoogle Scholar
  • 8 Emanuele E, D'Angelo A, Tomaino C. , et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 2005; 62 (11) 1734-1736
    CrossrefPubMedGoogle Scholar
  • 9 Prasad K, Dhar I, Zhou Q, Elmoselhi H, Shoker M, Shoker A. AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease. Mol Cell Biochem 2016; 423 (1-2): 105-114
    CrossrefPubMedGoogle Scholar
  • 10 Yan SF, Ramasamy R, Schmidt AM. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med (Berl) 2009; 87 (03) 235-247
    CrossrefPubMedGoogle Scholar
  • 11 Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 1999; 22 (09) 1543-1548
    CrossrefPubMedGoogle Scholar
  • 12 Schneiderman N, Ironson G, Siegel SD. Stress and health: psychological, behavioral, and biological determinants. Annu Rev Clin Psychol 2005; 1: 607-628
    CrossrefPubMedGoogle Scholar
  • 13 Prasad K. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality. Int J Angiol 2014; 23 (01) 11-16
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994; 70 (02) 138-151
    PubMedGoogle Scholar
  • 15 Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 1995; 34 (34) 10872-10878
    CrossrefPubMedGoogle Scholar
  • 16 Prasad K. Soluble receptor for advanced glycation end products (sRAGE) and cardiovascular disease. Int J Angiol 2006; 15: 57-68
    PubMedGoogle Scholar
  • 17 Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992; 23: 1-34
    CrossrefPubMedGoogle Scholar
  • 18 Ahmed N. Advanced glycation endproducts–role in pathology of diabetic complications. Diabetes Res Clin Pract 2005; 67 (01) 3-21
    CrossrefPubMedGoogle Scholar
  • 19 Kaneko M, Bucciarelli L, Hwang YC. , et al. Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury. Ann N Y Acad Sci 2005; 1043: 702-709
    CrossrefPubMedGoogle Scholar
  • 20 Weiss MF, Erhard P, Kader-Attia FA. , et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int 2000; 57 (06) 2571-2585
    CrossrefPubMedGoogle Scholar
  • 21 Ahmed MU, Thorpe SR, Baynes JW. Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986; 261 (11) 4889-4894
    PubMedGoogle Scholar
  • 22 Uribarri J, Woodruff S, Goodman S. , et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010; 110 (06) 911-16.e12
    CrossrefPubMedGoogle Scholar
  • 23 Uribarri J, del Castillo MD, de la Maza MP. , et al. Dietary advanced glycation end products and their role in health and disease. Adv Nutr 2015; 6 (04) 461-473
    CrossrefPubMedGoogle Scholar
  • 24 Prasad K, Dhar I, Caspar-Bell G. Role of advanced glycation end products and its receptors in the pathogenesis of cigarette smoke-induced cardiovascular disease. Int J Angiol 2015; 24 (02) 75-80
    PubMedGoogle Scholar
  • 25 Koschinsky T, He CJ, Mitsuhashi T. , et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 1997; 94 (12) 6474-6479
    CrossrefPubMedGoogle Scholar
  • 26 Sandu O, Song K, Cai W, Zheng F, Uribarri J, Vlassara H. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes 2005; 54 (08) 2314-2319
    CrossrefPubMedGoogle Scholar
  • 27 Liardon RD-GD, Philippossian G, Finot PA. Identification of N. epsilon.-carboxymethyllysine: a new Maillard reaction product in rat urine. J Agric Food Chem 1987; 35 (03) 427-431
    CrossrefPubMedGoogle Scholar
  • 28 Semba RD, Ang A, Talegawkar S. , et al. Dietary intake associated with serum versus urinary carboxymethyl-lysine, a major advanced glycation end product, in adults: the Energetics Study. Eur J Clin Nutr 2012; 66 (01) 3-9
    CrossrefPubMedGoogle Scholar
  • 29 Neeper M, Schmidt AM, Brett J. , et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267 (21) 14998-15004
    CrossrefPubMedGoogle Scholar
  • 30 Stern DM, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 2002; 1 (01) 1-15
    CrossrefPubMedGoogle Scholar
  • 31 Hofmann MA, Drury S, Fu C. , et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97 (07) 889-901
    CrossrefPubMedGoogle Scholar
  • 32 Taguchi A, Blood DC, del Toro G. , et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405 (6784): 354-360
    CrossrefPubMedGoogle Scholar
  • 33 Yan SD, Zhu H, Zhu A. , et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000; 6 (06) 643-651
    CrossrefPubMedGoogle Scholar
  • 34 Schmidt AM, Hasu M, Popov D. , et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A 1994; 91 (19) 8807-8811
    CrossrefPubMedGoogle Scholar
  • 35 Schmidt AM, Hori O, Chen JX. , et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96 (03) 1395-1403
    CrossrefPubMedGoogle Scholar
  • 36 Tanaka S, Avigad G, Brodsky B, Eikenberry EF. Glycation induces expansion of the molecular packing of collagen. J Mol Biol 1988; 203 (02) 495-505
    CrossrefPubMedGoogle Scholar
  • 37 Striker LJ, Striker GE. Administration of AGEs in vivo induces extracellular matrix gene expression. Nephrol Dial Transplant 1996; 11 (Suppl. 05) 62-65
    PubMedGoogle Scholar
  • 38 Reiser K, McCormick RJ, Rucker RB. Enzymatic and nonenzymatic cross-linking of collagen and elastin. FASEB J 1992; 6 (07) 2439-2449
    CrossrefPubMedGoogle Scholar
  • 39 Zieman S, Kass D. Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovascular disease. Congest Heart Fail 2004; 10 (03) 144-149 , quiz 150–151
    CrossrefPubMedGoogle Scholar
  • 40 Ahmed N, Lüthen R, Häussinger D. , et al. Increased protein glycation in cirrhosis and therapeutic strategies to prevent it. Ann N Y Acad Sci 2005; 1043: 718-724
    CrossrefPubMedGoogle Scholar
  • 41 Poulsen MW, Hedegaard RV, Andersen JM. , et al. Advanced glycation endproducts in food and their effects on health. Food Chem Toxicol 2013; 60: 10-37
    CrossrefPubMedGoogle Scholar
  • 42 Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A 1993; 90 (14) 6434-6438
    CrossrefPubMedGoogle Scholar
  • 43 Steinbrecher UP, Witztum JL. Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 1984; 33 (02) 130-134
    CrossrefPubMedGoogle Scholar
  • 44 Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem 1992; 267 (06) 4143-4151
    CrossrefPubMedGoogle Scholar
  • 45 Makita T, Tanaka A, Numano F. Effect of glycated low density lipoprotein on smooth muscle cell proliferation. Int Angiol 1999; 18 (04) 331-334
    Google Scholar
  • 46 Horiuchi S, Sakamoto Y, Sakai M. Scavenger receptors for oxidized and glycated proteins. Amino Acids 2003; 25 (3-4): 283-292
    CrossrefPubMedGoogle Scholar
  • 47 Brown BE, Dean RT, Davies MJ. Glycation of low-density lipoproteins by methylglyoxal and glycolaldehyde gives rise to the in vitro formation of lipid-laden cells. Diabetologia 2005; 48 (02) 361-369
    CrossrefPubMedGoogle Scholar
  • 48 Barnaby OS, Cerny RL, Clarke W, Hage DS. Comparison of modification sites formed on human serum albumin at various stages of glycation. Clin Chim Acta 2011; 412 (3-4): 277-285
    CrossrefPubMedGoogle Scholar
  • 49 Rubenstein DA, Yin W. Glycated albumin modulates platelet susceptibility to flow induced activation and aggregation. Platelets 2009; 20 (03) 206-215
    CrossrefPubMedGoogle Scholar
  • 50 Dunn EJ, Philippou H, Ariëns RA, Grant PJ. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006; 49 (05) 1071-1080
    CrossrefPubMedGoogle Scholar
  • 51 Jörneskog G, Hansson LO, Wallen NH, Yngen M, Blombäck M. Increased plasma fibrin gel porosity in patients with type I diabetes during continuous subcutaneous insulin infusion. J Thromb Haemost 2003; 1 (06) 1195-1201
    CrossrefPubMedGoogle Scholar
  • 52 Ahmad S, Moinuddin Khan RH, Ali A. Physicochemical studies on glycation-induced structural changes in human IgG. IUBMB Life 2012; 64 (02) 151-156
    CrossrefPubMedGoogle Scholar
  • 53 Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280 (05) E685-E694
    CrossrefPubMedGoogle Scholar
  • 54 Fleming TH, Humpert PM, Nawroth PP, Bierhaus A. Reactive metabolites and AGE/RAGE-mediated cellular dysfunction affect the aging process: a mini-review. Gerontology 2011; 57 (05) 435-443
    CrossrefPubMedGoogle Scholar
  • 55 Bierhaus A, Humpert PM, Morcos M. , et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 2005; 83 (11) 876-886
    CrossrefPubMedGoogle Scholar
  • 56 Reznikov LL, Waksman J, Azam T. , et al. Effect of advanced glycation end products on endotoxin-induced TNF-alpha, IL-1beta and IL-8 in human peripheral blood mononuclear cells. Clin Nephrol 2004; 61 (05) 324-336
    CrossrefPubMedGoogle Scholar
  • 57 Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 1993; 91 (05) 2155-2168
    CrossrefPubMedGoogle Scholar
  • 58 Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A 1992; 89 (24) 12043-12047
    CrossrefPubMedGoogle Scholar
  • 59 Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988; 240 (4858): 1546-1548
    CrossrefPubMedGoogle Scholar
  • 60 Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci U S A 1990; 87 (22) 9010-9014
    CrossrefPubMedGoogle Scholar
  • 61 Kirstein M, Aston C, Hintz R, Vlassara H. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 1992; 90 (02) 439-446
    CrossrefPubMedGoogle Scholar
  • 62 Klein RL, Laimins M, Lopes-Virella MF. Isolation, characterization, and metabolism of the glycated and nonglycated subfractions of low-density lipoproteins isolated from type I diabetic patients and nondiabetic subjects. Diabetes 1995; 44 (09) 1093-1098
    CrossrefPubMedGoogle Scholar
  • 63 Wautier JL, Zoukourian C, Chappey O. , et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996; 97 (01) 238-243
    CrossrefPubMedGoogle Scholar
  • 64 Esposito C, Gerlach H, Brett J, Stern D, Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989; 170 (04) 1387-1407
    CrossrefPubMedGoogle Scholar
  • 65 Sakata N, Meng J, Takebayashi S. Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. J Atheroscler Thromb 2000; 7 (03) 169-176
    CrossrefPubMedGoogle Scholar
  • 66 Sakaguchi T, Yan SF, Yan SD. , et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003; 111 (07) 959-972
    CrossrefPubMedGoogle Scholar
  • 67 Mannervik B. Molecular enzymology of the glyoxalase system. Drug Metabol Drug Interact 2008; 23 (1-2): 13-27
    PubMedGoogle Scholar
  • 68 Thornalley PJ. Glyoxalase I--structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 2003; 31 (Pt 6): 1343-1348
    CrossrefPubMedGoogle Scholar
  • 69 Shinohara M, Thornalley PJ, Giardino I. , et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest 1998; 101 (05) 1142-1147
    CrossrefPubMedGoogle Scholar
  • 70 Ahmed U, Dobler D, Larkin SJ, Rabbani N, Thornalley PJ. Reversal of hyperglycemia-induced angiogenesis deficit of human endothelial cells by overexpression of glyoxalase 1 in vitro. Ann N Y Acad Sci 2008; 1126: 262-264
    CrossrefPubMedGoogle Scholar
  • 71 Brouwers O, Niessen PM, Haenen G. , et al. Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress. Diabetologia 2010; 53 (05) 989-1000
    CrossrefPubMedGoogle Scholar
  • 72 Gangadhariah MH, Mailankot M, Reneker L, Nagaraj RH. Inhibition of methylglyoxal-mediated protein modification in glyoxalase I overexpressing mouse lenses. J Ophthalmol 2010; 2010 (10) 274317
    PubMedGoogle Scholar
  • 73 Miller AG, Smith DG, Bhat M, Nagaraj RH. Glyoxalase I is critical for human retinal capillary pericyte survival under hyperglycemic conditions. J Biol Chem 2006; 281 (17) 11864-11871
    CrossrefPubMedGoogle Scholar
  • 74 Kuhla B, Boeck K, Lüth HJ. , et al. Age-dependent changes of glyoxalase I expression in human brain. Neurobiol Aging 2006; 27 (06) 815-822
    CrossrefPubMedGoogle Scholar
  • 75 Yang Z, Makita Z, Horii Y. , et al. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins. J Exp Med 1991; 174 (03) 515-524
    CrossrefPubMedGoogle Scholar
  • 76 Vlassara H, Li YM, Imani F. , et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995; 1 (06) 634-646
    CrossrefPubMedGoogle Scholar
  • 77 Pugliese G, Pricci F, Leto G. , et al. The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression. Diabetes 2000; 49 (07) 1249-1257
    CrossrefPubMedGoogle Scholar
  • 78 Goh SY, Cooper ME. Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008; 93 (04) 1143-1152
    CrossrefPubMedGoogle Scholar
  • 79 Vlassara H, Brownlee M, Cerami A. Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors. J Exp Med 1986; 164 (04) 1301-1309
    CrossrefPubMedGoogle Scholar
  • 80 Lu C, He JC, Cai W, Liu H, Zhu L, Vlassara H. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci U S A 2004; 101 (32) 11767-11772
    CrossrefPubMedGoogle Scholar
  • 81 He CJ, Koschinsky T, Buenting C, Vlassara H. Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE. Mol Med 2001; 7 (03) 159-168
    CrossrefPubMedGoogle Scholar
  • 82 Coughlan MT, Thallas-Bonke V, Pete J. , et al. Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?. Endocrinology 2007; 148 (02) 886-895
    CrossrefPubMedGoogle Scholar
  • 83 Cai W, He JC, Zhu L, Lu C, Vlassara H. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci U S A 2006; 103 (37) 13801-13806
    CrossrefPubMedGoogle Scholar
  • 84 Saito A, Nagai R, Tanuma A. , et al. Role of megalin in endocytosis of advanced glycation end products: implications for a novel protein binding to both megalin and advanced glycation end products. J Am Soc Nephrol 2003; 14 (05) 1123-1131
    CrossrefPubMedGoogle Scholar
  • 85 Vlassara H, Torreggiani M, Post JB, Zheng F, Uribarri J, Striker GE. Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging. Kidney Int Suppl 2009; (114) S3-S11
    PubMedGoogle Scholar
  • 86 Makita Z, Radoff S, Rayfield EJ. , et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325 (12) 836-842
    CrossrefPubMedGoogle Scholar
  • 87 He CJ, Zheng F, Stitt A, Striker L, Hattori M, Vlassara H. Differential expression of renal AGE-receptor genes in NOD mice: possible role in nonobese diabetic renal disease. Kidney Int 2000; 58 (05) 1931-1940
    CrossrefPubMedGoogle Scholar
  • 88 Vlassara H, Striker GE. The role of advanced glycation end-products in the etiology of insulin resistance and diabetes. US Endocrinol 2010; 6 (01) 14-19
    PubMedGoogle Scholar
  • 89 Vlassara H, Cai W, Goodman S. , et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab 2009; 94 (11) 4483-4491
    CrossrefPubMedGoogle Scholar
  • 90 Tam XH, Shiu SW, Leng L, Bucala R, Betteridge DJ, Tan KC. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. Clin Sci (Lond) 2011; 120 (02) 81-89
    CrossrefPubMedGoogle Scholar
  • 91 Yonekura H, Yamamoto Y, Sakurai S. , et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370 (Pt 3): 1097-1109
    CrossrefPubMedGoogle Scholar
  • 92 Koyama H, Shoji T, Yokoyama H. , et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25 (12) 2587-2593
    CrossrefPubMedGoogle Scholar
  • 93 Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108 (07) 949-955
    CrossrefPubMedGoogle Scholar
  • 94 Malherbe P, Richards JG, Gaillard H. , et al. cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res Mol Brain Res 1999; 71 (02) 159-170
    CrossrefPubMedGoogle Scholar
  • 95 Koyama H, Yamamoto H, Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med 2007; 13 (11-12): 625-635
    CrossrefPubMedGoogle Scholar
  • 96 Zhou Z, Wang K, Penn MS. , et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 2003; 107 (17) 2238-2243
    CrossrefPubMedGoogle Scholar
  • 97 Park L, Raman KG, Lee KJ. , et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4 (09) 1025-1031
    CrossrefPubMedGoogle Scholar
  • 98 McNair ED, Wells CR, Mabood Qureshi A. , et al. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention. Clin Cardiol 2010; 33 (11) 678-685
    CrossrefPubMedGoogle Scholar
  • 99 Ramful D, Tarnus E, Rondeau P, Da Silva CR, Bahorun T, Bourdon E. Citrus fruit extracts reduce advanced glycation end products (AGEs)- and H2O2-induced oxidative stress in human adipocytes. J Agric Food Chem 2010; 58 (20) 11119-11129
    CrossrefPubMedGoogle Scholar
  • 100 Liu W, Ma H, Frost L, Yuan T, Dain JA, Seeram NP. Pomegranate phenolics inhibit formation of advanced glycation endproducts by scavenging reactive carbonyl species. Food Funct 2014; 5 (11) 2996-3004
    CrossrefPubMedGoogle Scholar
  • 101 Wang W, Yagiz Y, Buran TJ, Nunes MCN, Gu L. Phytochemicals from berries and grapes inhibited the formation of advanced glycation end-products by scavenging reactive carbonyls. Food Res Int 2011; 44 (09) 2666-2673
    CrossrefPubMedGoogle Scholar
  • 102 Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232 (4758): 1629-1632
    CrossrefPubMedGoogle Scholar
  • 103 Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 1994; 37 (01) 32-35
    CrossrefPubMedGoogle Scholar
  • 104 Bolton WK, Cattran DC, Williams ME. , et al; ACTION I Investigator Group. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004; 24 (01) 32-40
    CrossrefPubMedGoogle Scholar
  • 105 Freedman BI, Wuerth JP, Cartwright K. , et al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 1999; 20 (05) 493-510
    CrossrefPubMedGoogle Scholar
  • 106 Sebeková K, Gazdíková K, Syrová D. , et al. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J Hum Hypertens 2003; 17 (04) 265-270
    CrossrefPubMedGoogle Scholar
  • 107 Yoshida T, Yamagishi S, Matsui T. , et al. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res 2008; 36 (02) 237-243
    CrossrefPubMedGoogle Scholar
  • 108 Komiya N, Hirose H, Saisho Y, Saito I, Itoh H. Effects of 12-month valsartan therapy on glycation and oxidative stress markers in type 2 diabetic subjects with hypertension. Int Heart J 2008; 49 (06) 681-689
    CrossrefPubMedGoogle Scholar
  • 109 Saha SA, LaSalle BK, Clifton GD, Short RA, Tuttle KR. Modulation of advanced glycation end products by candesartan in patients with diabetic kidney disease--a dose-response relationship study. Am J Ther 2010; 17 (06) 553-558
    CrossrefPubMedGoogle Scholar
  • 110 Nozue T, Yamagishi S, Takeuchic M. , et al. Effect of statins on the serum soluble form of receptor for advanced glycation end-products and its association with coronary atherosclerosis in patients with angina pectoris. IJC Metab Endocr 2014; 4: 47-52
    PubMedGoogle Scholar
  • 111 Scharnagl H, Stojakovic T, Winkler K, Rosinger S, März W, Boehm BO. The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2007; 115 (06) 372-375
    Article in Thieme ConnectPubMedGoogle Scholar
  • 112 Diamanti-Kandarakis E, Alexandraki K, Piperi C. , et al. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. Metabolism 2007; 56 (01) 129-134
    CrossrefPubMedGoogle Scholar
  • 113 Rahbar S, Natarajan R, Yerneni K, Scott S, Gonzales N, Nadler JL. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 2000; 301 (1-2): 65-77
    CrossrefPubMedGoogle Scholar
  • 114 Abdul HM, Butterfield DA. Involvement of PI3K/PKG/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyl-L-carnitine and alpha-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. Free Radic Biol Med 2007; 42 (03) 371-384
    CrossrefPubMedGoogle Scholar
  • 115 Urios P, Grigorova-Borsos AM, Sternberg M. Aspirin inhibits the formation of pentosidine, a cross-linking advanced glycation end product, in collagen. Diabetes Res Clin Pract 2007; 77 (02) 337-340
    CrossrefPubMedGoogle Scholar
  • 116 Nandhini AT, Thirunavukkarasu V, Anuradha CV. Taurine prevents collagen abnormalities in high fructose-fed rats. Indian J Med Res 2005; 122 (02) 171-177
    PubMedGoogle Scholar
  • 117 Mizutani K, Ikeda K, Yamori Y. Resveratrol inhibits AGEs-induced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Biochem Biophys Res Commun 2000; 274 (01) 61-67
    CrossrefPubMedGoogle Scholar
  • 118 Tang Y, Chen A. Curcumin eliminates the effect of advanced glycation end-products (AGEs) on the divergent regulation of gene expression of receptors of AGEs by interrupting leptin signaling. Lab Invest 2014; 94 (05) 503-516
    CrossrefPubMedGoogle Scholar
  • 119 Hammes HP, Du X, Edelstein D. , et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9 (03) 294-299
    CrossrefPubMedGoogle Scholar
  • 120 Metz TO, Alderson NL, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys 2003; 419 (01) 41-49
    CrossrefPubMedGoogle Scholar
  • 121 Subratty AH, Aukburally N, Jowaheer V, Joonus N. Vitamin C and urea inhibit the formation of advanced glycation end products in vitro. Nutr Food Sci 2010; 40 (05) 456-465
    CrossrefPubMedGoogle Scholar
  • 122 Salum E, Kals J, Kampus P. , et al. Vitamin D reduces deposition of advanced glycation end-products in the aortic wall and systemic oxidative stress in diabetic rats. Diabetes Res Clin Pract 2013; 100 (02) 243-249
    CrossrefPubMedGoogle Scholar
  • 123 Baragetti I, Furiani S, Vettoretti S. , et al. Role of vitamin E-coated membrane in reducing advanced glycation end products in hemodialysis patients: a pilot study. Blood Purif 2006; 24 (04) 369-376
    CrossrefPubMedGoogle Scholar
  • 124 Vasan S, Zhang X, Zhang X. , et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996; 382 (6588): 275-278
    CrossrefPubMedGoogle Scholar
  • 125 Kass DA, Shapiro EP, Kawaguchi M. , et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104 (13) 1464-1470
    CrossrefPubMedGoogle Scholar
  • 126 Cuccurullo C, Iezzi A, Fazia ML. , et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006; 26 (12) 2716-2723
    CrossrefPubMedGoogle Scholar
  • 127 Xu L, Zang P, Feng B, Qian Q. Atorvastatin inhibits the expression of RAGE induced by advanced glycation end products on aortas in healthy Sprague-Dawley rats. Diabetol Metab Syndr 2014; 6 (01) 102
    CrossrefPubMedGoogle Scholar
  • 128 Nakamura K, Yamagishi S, Nakamura Y. , et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 2005; 70 (03) 137-141
    CrossrefPubMedGoogle Scholar
  • 129 Fan Q, Liao J, Kobayashi M. , et al. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 2004; 19 (12) 3012-3020
    CrossrefPubMedGoogle Scholar
  • 130 Ouslimani N, Mahrouf M, Peynet J. , et al. Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor 1. Metabolism 2007; 56 (03) 308-313
    CrossrefPubMedGoogle Scholar
  • 131 Marx N, Walcher D, Ivanova N. , et al. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 2004; 53 (10) 2662-2668
    CrossrefPubMedGoogle Scholar
  • 132 Yamagishi S, Takeuchi M. Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. Drugs Exp Clin Res 2004; 30 (04) 169-175
    PubMedGoogle Scholar
  • 133 Lin J, Tang Y, Kang Q, Feng Y, Chen A. Curcumin inhibits gene expression of receptor for advanced glycation end-products (RAGE) in hepatic stellate cells in vitro by elevating PPARγ activity and attenuating oxidative stress. Br J Pharmacol 2012; 166 (08) 2212-2227
    CrossrefPubMedGoogle Scholar
  • 134 Jing YH, Chen KH, Yang SH, Kuo PC, Chen JK. Resveratrol ameliorates vasculopathy in STZ-induced diabetic rats: role of AGE-RAGE signalling. Diabetes Metab Res Rev 2010; 26 (03) 212-222
    CrossrefPubMedGoogle Scholar
  • 135 Prasad K. Resveratrol, wine, and atherosclerosis. Int J Angiol 2012; 21 (01) 7-18
    Article in Thieme ConnectPubMedGoogle Scholar
  • 136 Forbes JM, Thorpe SR, Thallas-Bonke V. , et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005; 16 (08) 2363-2372
    CrossrefPubMedGoogle Scholar
  • 137 Tam HL, Shiu SW, Wong Y, Chow WS, Betteridge DJ, Tan KC. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis 2010; 209 (01) 173-177
    CrossrefPubMedGoogle Scholar
  • 138 Quade-Lyssy P, Kanarek AM, Baiersdörfer M, Postina R, Kojro E. Statins stimulate the production of a soluble form of the receptor for advanced glycation end products. J Lipid Res 2013; 54 (11) 3052-3061
    CrossrefPubMedGoogle Scholar
  • 139 Haddad M, Knani I, Bouzidi H, Berriche O, Hammami M, Kerkeni M. Plasma levels of pentosidine, carboxymethyl-lysine, soluble receptor for advanced glycation end products, and metabolic syndrome: the metformin effect. Dis Markers 2016; 2016 (16) 6248264
    PubMedGoogle Scholar
  • 140 Lam JK, Wang Y, Shiu SW, Wong Y, Betteridge DJ, Tan KC. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE). Diabet Med 2013; 30 (06) 702-709
    CrossrefPubMedGoogle Scholar
  • 141 Tan KC, Chow WS, Tso AW. , et al. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia 2007; 50 (09) 1819-1825
    CrossrefPubMedGoogle Scholar
  • 142 Tang SC, Wang YC, Li YI. , et al. Functional role of soluble receptor for advanced glycation end products in stroke. Arterioscler Thromb Vasc Biol 2013; 33 (03) 585-594
    CrossrefPubMedGoogle Scholar
  • 143 Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003; 56 (11) 1129-1135
    CrossrefPubMedGoogle Scholar